Emcure Pharmaceuticals Ltd

Emcure Pharmaceuticals Ltd

Emcure Pharmaceuticals Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with the Board of Directors approving the results at its meeting held on August 6, 2026. The company has enclosed the unaudited financial results and a limited review report by its statutory auditors, B S R & Co. LLP, with the announcement.

Emcure Pharmaceuticals Ltd

Emcure Pharmaceuticals Ltd has announced the outcome of its Board Meeting held on August 06, 2026. The Board has approved the unaudited financial results for the quarter ended June 30, 2026, and has also made several other key appointments and re-constituted some of its committees. Mr. Berjis Desai has retired as Chairman and Director, and Mr. Satish Mehta has been appointed as the new Chairman. Mr. Raghu Kumar has been appointed as an Additional Director, and Mr. Samit Mehta has been appointed as the Chief Operating Officer.

Emcure Pharmaceuticals Ltd

Emcure Pharmaceuticals Ltd has completed the acquisition of 12.05% of Gennova Biopharmaceuticals Ltd's shares, making Gennova a wholly-owned subsidiary. The acquisition was completed on July 21, 2026, for an aggregate consideration of Rs. 2,318.7 Million.

Emcure Pharmaceuticals Ltd

Emcure Pharmaceuticals Ltd has announced the completion of the 2nd term of Independent Director Mr. P.S. Jayakumar, who will cease to be a Director and Chairman/Member of various Board Committees with effect from July 21, 2026.